Xoma
Executive Summary
Biotech firm files to register $ 50 mil. in convertible subordinated debentures with the Securities and Exchange Commission. Proceeds are expected to be used to support expansion of manufacturing capacity for Xomen-E5 and XomaZyme-H65, development of a marketing and sales force for XomaZyme-H65 and working capital requirements. Dillon Reed, Alex. Brown and Oppenheimer are the underwriters.
You may also be interested in...
QUOTED. 25 February 2021. Adam Saltman.
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
J&J's COVID-19 Vaccine May Face Efficacy Comparison Questions At US FDA Panel Review
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: